Vaxart Inc Stock Price, News & Analysis

Vaxart (NASDAQ: VXRT) released promising results from its Hamster Challenge Study, indicating that all hamsters receiving two oral doses of its COVID-19 vaccine candidate did not experience systemic weight loss, a key protective measure. Dr. Sean Tucker highlighted that these results validate the vaccine's potential against COVID-19 as the company prepares for human clinical trials. The study showed that unvaccinated hamsters lost significant weight and exhibited lung issues, whereas vaccinated ones maintained or gained weight (p<0.001). Vaxart aims to provide a convenient oral vaccine solution.

Vaxart, a clinical-stage biotechnology firm, announced the dosing of the first subject in its Phase 1 study for VXA-CoV2-1, an oral COVID-19 vaccine candidate. The open-label trial aims to assess safety and immunogenicity in 48 healthy adults. Preclinical data suggest the vaccine can trigger significant systemic and mucosal immune responses. Enrollment is expected to finish by early November 2020, with initial clinical data available shortly thereafter. Vaxart's oral tablet vaccine may simplify distribution and administration compared to traditional injectable vaccines.

Vaxart, a clinical-stage biotechnology company, announced the FDA's approval for its Investigational New Drug (IND) application for a Phase 1 trial of its oral COVID-19 vaccine. Recruitment for the trial is set to start this month, targeting healthy adults aged 18 to 55. The primary focus is on safety and reactogenicity, while secondary aims include measuring immune response duration. Additionally, Vaxart expects results from hamster and non-human primate challenge studies this October. The oral vaccine platform offers advantages like easier distribution due to stability at room temperature.

Vaxart, Inc. (NASDAQ: VXRT) announced the appointment of Karen J. Wilson to its Board of Directors and as chair of the Audit Committee. With over 30 years in finance within the life sciences sector, Wilson's experience is expected to bolster Vaxart's growth as they advance their oral COVID-19 vaccine candidate. CEO Andrei Floroiu highlighted her expertise as a significant asset for the company, which is focused on developing oral vaccines for various infectious diseases. Vaxart’s innovative tablet vaccines aim to simplify distribution and enhance pandemic response.

Vaxart, Inc. (NASDAQ: VXRT) recently announced a study in the Journal of Infectious Diseases highlighting that norovirus gastroenteritis costs the U.S. approximately $10.6 billion annually, primarily due to sporadic cases rather than publicized outbreaks. Conducted by PHICOR, the study suggests over 50% of these costs occur during winter months, emphasizing the need for timely preventative measures. Furthermore, productivity losses account for 89% of overall costs, underscoring the substantial economic burden. Vaxart supports the research to advance its oral norovirus vaccine program.

Vaxart, Inc. (NASDAQ: VXRT) announced it raised approximately $90 million through its At-the-Market facility, selling 11.2 million shares at $7.98 each. The funds will support clinical development and product manufacturing. SVB Leerink and B. Riley FBR are involved as sales agents. The offering was made under an effective shelf registration statement filed with the SEC. Vaxart focuses on developing oral vaccines for infectious diseases, including COVID-19, with the goal of achieving easier distribution compared to injectable vaccines.

Vaxart, a clinical-stage biotechnology company, has signed a Memorandum of Understanding with AMS for the large-scale production of its oral COVID-19 vaccine. This partnership aims to enable the manufacture of over a billion doses annually, facilitating distribution in the US, Europe, and other regions. CEO Andrei Floroiu highlighted the logistical advantages of Vaxart's room-temperature stable tablet vaccine, which may provide enhanced protection against airborne viruses. The company continues to focus on developing oral vaccines for various infectious diseases.

Vaxart, a clinical-stage biotech firm, announced its inclusion in the Russell 3000 Index effective June 29, 2020. This membership enhances the company's visibility among institutional investors and could increase stock liquidity. Vaxart is focused on developing oral vaccines for various infectious diseases, including COVID-19. The Russell 3000 is a benchmark for approximately $9 trillion in assets, which could further drive Vaxart's growth. CEO Andrei Floroiu expressed optimism about the company's innovative oral vaccine approach and its potential advantages over traditional injectables.

Vaxart, Inc. (NasdaqCM: VXRT) has appointed Andrei Floroiu as the new Chief Executive Officer. With extensive experience in the biopharma sector, particularly in vaccine and business development, Floroiu aims to drive the company's growth, especially in light of COVID-19 vaccine development. He previously held executive roles at Agenus, where he structured significant partnerships. Vaxart currently holds approximately $30 million in cash, which supports its innovation in oral recombinant vaccine technology, designed for various infectious diseases.